IGC Pharma Reports Financial and Strategic Milestones for Q2 FY2025

IGC Pharma, Inc. announced substantial developments in its Alzheimer's treatments pipeline for the second fiscal quarter of 2025, ended September 30, 2024. Key advancements include TGR-63's progress in crossing the blood-brain barrier and the AI-driven identification of IGC-1A as a GLP-1 agonist. Further, preclinical success with IGC-1C enhances its Alzheimer's portfolio.

Financially, IGC saw a 42% revenue increase, amounting to $412,000, largely due to growth in its Life Science Segment. Strategic cost reduction efforts led to a 25% decrease in SG&A expenses. R&D expenses decreased by 28%, focusing on cost efficiency while advancing Phase 2 trials for IGC-AD1.

The net loss narrowed to $1.7 million, compared to $2.5 million a year prior. The company maintains a strong financial position with no utilization of its $12 million credit facility.